Max Robotics — Global Service Robot Directory + US Certification

About

Luigi Bevilacqua is a urological surgeon and researcher whose work centers on advancing prostate cancer diagnostics and improving functional outcomes after surgery. His most impactful contribution is the pioneering application of ex vivo fluorescence confocal microscopy (FCM) for real-time pathological examination of prostatic tissue. In a landmark 2019 study (85 citations), Bevilacqua demonstrated that FCM can provide fast, microscopic imaging of unfixed specimens, enabling immediate assessment of both non-neoplastic and cancerous prostate tissue. This innovation holds the potential to transform intraoperative decision-making by reducing reliance on traditional, time-consuming frozen section analysis. Beyond diagnostics, Bevilacqua has investigated perioperative techniques to enhance patient quality of life, notably examining whether the topical hemostatic agent Floseal® adversely affects erectile function recovery following nerve-sparing robot-assisted radical prostatectomy (2017, 8 citations). His research bridges cutting-edge optical technology with practical surgical concerns, aiming to refine both the accuracy of cancer detection and the preservation of critical functions. Bevilacqua’s work represents a meaningful step toward integrating real-time pathology into urological practice, offering a glimpse of a future where surgeons can make more informed, tissue-sparing decisions during prostate cancer treatment.